Cited by 548Tuberculosis Research and EpidemiologyImmune responses and vaccinationsInfectious Diseases and Tuberculosis

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Metformin as adjunct antituberculosis therapy

Singhal, Amit, Jie, Liu, Kumar, Pavanish, Hong, Gan Suay, Leow, Melvin Khee-Shing, Paleja, Bhairav, Tsenova, Liana, Kurepina, Natalia, Chen, Jinmiao, Zolezzi, Francesca, Kreiswirth, Barry, Poidinger, Michael, Chee, Cynthia, Kaplan, Gilla, Wang, Yee Tang, De Libero, Gennaro·2014·Science Translational Medicine

DOI 10.1126/scitranslmed.3009885

Open this paper in CoChat — free account

Abstract

The global burden of tuberculosis (TB) morbidity and mortality remains immense. A potential new approach to TB therapy is to augment protective host immune responses. We report that the antidiabetic drug metformin (MET) reduces the intracellular growth of Mycobacterium tuberculosis (Mtb) in an AMPK (adenosine monophosphate-activated protein kinase)-dependent manner. MET controls the growth of drug-resistant Mtb strains, increases production of mitochondrial reactive oxygen species, and facilitates phagosome-lysosome fusion. In Mtb-infected mice, use of MET ameliorated lung pathology, reduced chronic inflammation, and enhanced the specific immune response and the efficacy of conventional TB drugs. Moreover, in two separate human cohorts, MET treatment was associated with improved control of Mtb infection and decreased disease severity. Collectively, these data indicate that MET is a promising candidate host-adjunctive therapy for improving the effective treatment of TB.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3009885

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,328
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
Mihaylova, M. M., & Shaw, R. J. (2011) · Nature Cell Biology · doi:10.1038/ncb2329 · Cited by 2,923
Autophagy Is a Defense Mechanism Inhibiting BCG and Mycobacterium tuberculosis Survival in Infected Macrophages
Gutierrez, M. G., Master, S. S., Singh, S. B., Taylor, G. A., Colombo, M. I., & Deretic, V. (2004) · Cell · doi:10.1016/j.cell.2004.11.038 · Cited by 2,252
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis
Berry, M. P. R., Graham, C. M., McNab, F. W., Xu, Z., Bloch, S. A. A., Oni, T., Wilkinson, K. A., Banchereau, R., Skinner, J., Wilkinson, R. J., et al. (2010) · Nature · doi:10.1038/nature09247 · Cited by 1,898
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Tlr signalling augments macrophage bactericidal activity through mitochondrial ros
West, A. P., Brodsky, I. E., Rahner, C., Woo, D. K., Erdjument-Bromage, H., Tempst, P., Walsh, M. C., Choi, Y., Shadel, G. S., & Ghosh, S. (2011) · Nature · doi:10.1038/nature09973 · Cited by 1,659

Show all 49 references

Sorted by citations

Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J., Chen, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0222-4 · Cited by 1,011
Mitochondria in the Regulation of Innate and Adaptive Immunity
Weinberg, S. E., Sena, L. A., & Chandel, N. S. (2015) · Immunity · doi:10.1016/j.immuni.2015.02.002 · Cited by 960
Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity
Arts, R. J. W., Novakovic, B., ter Horst, R., Carvalho, A., Bekkering, S., Lachmandas, E., Rodrigues, F., Silvestre, R., Cheng, S.-C., Wang, S.-Y., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.008 · Cited by 930
Host-directed therapies for bacterial and viral infections
Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S., & Bartenschlager, R. F. W. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.162 · Cited by 869
Metformin: update on mechanisms of action and repurposing potential
Foretz, M., Guigas, B., & Viollet, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00833-4 · Cited by 791
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686
Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
Zumla, A. I., Rao, M., Wallis, R. S., Kaufmann, S. H. E., Rustomjee, R., Mwaba, P., Vilaplana, C., Yeboah‐Manu, D., Chakaya, J. M., Ippolito, G., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00078-5 · Cited by 423
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
Tiberi, S., du Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mwaba, P., McHugh, T. D., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30110-5 · Cited by 403
Mitochondrial control of immunity: beyond ATP
Mehta, M., Weinberg, S. E., & Chandel, N. S. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.66 · Cited by 409
Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?
Brown, D. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4675 · Cited by 377
Advancing host-directed therapy for tuberculosis
Wallis, R. S., & Hafner, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3813 · Cited by 291
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R. S., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 300
Host-directed immunotherapy of viral and bacterial infections: past, present and future
Wallis, R. S., O’Garra, A., Sher, A., & Wack, A. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00734-z · Cited by 280
Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
Wallis, R. S., Maeurer, M. J., Mwaba, P., Chakaya, J. M., Rustomjee, R., Migliori, G. B., Marais, B. J., Schito, M. L., Churchyard, G., Swaminathan, S., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00070-0 · Cited by 271
Metformin Restores Tetracyclines Susceptibility against Multidrug Resistant Bacteria
Liu, Y., Jia, Y., Yang, K., Li, R., Xiao, X., Zhu, K., & Wang, Z. (2020) · Advanced Science · doi:10.1002/advs.201902227 · Cited by 242
Metabolic crosstalk between host and pathogen: sensing, adapting and competing
Olive, A. J., & Sassetti, C. M. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.12 · Cited by 231
Metformin attenuates lung fibrosis development via NOX4 suppression
Sato, N., Takasaka, N., Yoshida, M., Tsubouchi, K., Minagawa, S., Araya, J., Saito, N., Fujita, Y., Kurita, Y., Kobayashi, K., et al. (2016) · Respiratory Research · doi:10.1186/s12931-016-0420-x · Cited by 233
Diabetes and Tuberculosis
Restrepo, B. I. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.tnmi7-0023-2016 · Cited by 241
Therapeutic host-directed strategies to improve outcome in tuberculosis
Young, C., Walzl, G., & du Plessis, N. (2019) · Mucosal Immunology · doi:10.1038/s41385-019-0226-5 · Cited by 202
Diabetes and Lung Disease: An Underestimated Relationship
Khateeb, J., Fuchs, E., & Khamaisi, M. (2019) · The Review of Diabetic Studies · doi:10.1900/rds.2019.15.1 · Cited by 210
The Cellular and Molecular Basis of Translational Immunometabolism
Norata, G. D., Caligiuri, G., Chavakis, T., Matarese, G., Netea, M. G., Nicoletti, A., O'Neill, L. A. J., & Marelli‐Berg, F. M. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.023 · Cited by 197
The double burden of diabetes and global infection in low and middle-income countries
Dunachie, S. J., & Chamnan, P. (2018) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/try124 · Cited by 195
Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management
Liebenberg, D., Gordhan, B. G., & Kana, B. D. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.943545 · Cited by 220
Tumor necrosis factor induces pathogenic mitochondrial ROS in tuberculosis through reverse electron transport
Roca, F. J., Whitworth, L. J., Prag, H. A., Murphy, M. P., & Ramakrishnan, L. (2022) · Science · doi:10.1126/science.abh2841 · Cited by 177
Macrophage Autophagy and Bacterial Infections
Bah, A., & Vergne, I. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01483 · Cited by 169
The global diabetes epidemic: what does it mean for infectious diseases in tropical countries?
van Crevel, R., van de Vijver, S. J. M., & Moore, D. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30081-x · Cited by 160
Inducible antibacterial responses in macrophages
Sweet, M. J., Ramnath, D., Singhal, A., & Kapétanovic, R. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01080-y · Cited by 171
Self-citation
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
Scheen, A. J., Esser, N., & Paquot, N. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.02.003 · Cited by 159
Host‐directed therapy to combat mycobacterial infections*
Kilinç, G., Saris, A., Ottenhoff, T. H. M., & Haks, M. C. (2021) · Immunological Reviews · doi:10.1111/imr.12951 · Cited by 148
Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment
Degner, N. R., Wang, J., Golub, J. E., & Karakousis, P. C. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix819 · Cited by 136
Granulomas and Inflammation: Host-Directed Therapies for Tuberculosis
Ndlovu, H., & Marakalala, M. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00434 · Cited by 142
Host sirtuin 1 regulates mycobacterial immunopathogenesis and represents a therapeutic target against tuberculosis
Cheng, C. Y., Gutierrez, N. M., Marzuki, M., Lu, X., Foreman, T. W., Paleja, B. S., Lee, B. T. K., Balachander, A., Chen, J., Tsenova, L., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aaj1789 · Cited by 138
Self-citation
Modulation of Macrophage Immunometabolism: A New Approach to Fight Infections
Gauthier, T., & Chen, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.780839 · Cited by 137
The Echo of Pulmonary Tuberculosis: Mechanisms of Clinical Symptoms and Other Disease-Induced Systemic Complications
Luies, L., & du Preez, I. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-20 · Cited by 181
Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review
Kiran, D., Podell, B. K., Chambers, M. A., & Basaraba, R. J. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0537-x · Cited by 135
Immunometabolism during Mycobacterium tuberculosis Infection
Howard, N. C., & Khader, S. A. (2020) · Trends in Microbiology · doi:10.1016/j.tim.2020.04.010 · Cited by 134
Transient Hyperglycemia in Patients With Tuberculosis in Tanzania: Implications for Diabetes Screening Algorithms
Boillat‐Blanco, N., Ramaiya, K. L., Mganga, M., Minja, L. T., Bovet, P., Schindler, C., von Eckardstein, A., Gagneux, S., Daubenberger, C., Reither, K., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv568 · Cited by 121
Metformin Alters Human Host Responses to Mycobacterium tuberculosis in Healthy Subjects
Lachmandas, E., Eckold, C., Böhme, J., Koeken, V. A. C. M., Marzuki, M., Blok, B. A., Arts, R. J. W., Chen, J., Teng, K. W. W., Ratter, J. M., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz064 · Cited by 122
Self-citation
Glycemic Control and the Risk of Tuberculosis: A Cohort Study
Lee, P.-H., Fu, H. J., Lai, T.-C., Chiang, C., Chan, C., & Lin, H.-H. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002072 · Cited by 122
The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection
Giraud-Gatineau, A., Coya, J. M., Maure, A., Biton, A., Thomson, M., Bernard, E. M., Marrec, J., Gutierrez, M. G., Larrouy-Maumus, G. J., Brosch, R., et al. (2020) · eLife · doi:10.7554/elife.55692 · Cited by 113
Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies
Tiwari, D., & Martineau, A. R. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101672 · Cited by 114
Acquired immunodeficiencies and tuberculosis: focus on HIV / AIDS and diabetes mellitus
Ronacher, K., Joosten, S. A., van Crevel, R., Dockrell, H. M., Walzl, G., & Ottenhoff, T. H. M. (2015) · Immunological Reviews · doi:10.1111/imr.12257 · Cited by 110
High Prevalence and Heterogeneity of Diabetes in Patients With TB in South India
Kornfeld, H., West, K., Kane, K., Kumpatla, S., Zacharias, R. R., Martínez-Balzano, C., Li, W., & Viswanathan, V. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.02.675 · Cited by 106
The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy
Stek, C. J., Allwood, B., Walker, N. F., Wilkinson, R. J., Lynen, L., & Meintjes, G. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02603 · Cited by 105
Diabetes mellitus and tuberculosis: programmatic management issues
Harries, A. D., Kumar, A. M. V., Satyanarayana, S., Lin, Y., Zachariah, R., Lönnroth, K., & Kapur, A. (2015) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.15.0069 · Cited by 101
Metformin: Activation of 5′ AMP-activated protein kinase and its emerging potential beyond anti-hyperglycemic action
Goel, S. K., Singh, R. P., Singh, V., Singh, H., Kumari, P., Chopra, H., Sharma, R., Nepovimová, E., Vališ, M., Kuča, K., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1022739 · Cited by 113
The effects of metformin on gut microbiota and the immune system as research frontiers
Pollak, M. (2017) · Diabetologia · doi:10.1007/s00125-017-4352-x · Cited by 98
Protective effect of metformin against tuberculosis infections in diabetic patients: an observational study of south Indian tertiary healthcare facility
Marupuru, S., Senapati, P., Pathadka, S., Miraj, S. S., Unnikrishnan, M. K., & Manu, M. K. (2017) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2017.01.001 · Cited by 98
Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study
Penn‐Nicholson, A., Hraha, T. H., Thompson, E. G., Sterling, D., Mbandi, S. K., Wall, K. M., Fisher, M., Suliman, S., Shankar, S., Hanekom, W. A., et al. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002781 · Cited by 96
Compromised Metabolic Reprogramming Is an Early Indicator of CD8+ T Cell Dysfunction during Chronic Mycobacterium tuberculosis Infection
Russell, S., Lamprecht, D. A., Mandizvo, T., Jones, T., Naidoo, V., Addicott, K. W., Moodley, C., Ngcobo, B., Crossman, D. K., Wells, G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.034 · Cited by 103
The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives
Dookie, N., Ngema, S. L., Perumal, R., Naicker, N., Padayatchi, N., & Naidoo, K. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00180-19 · Cited by 106
Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease
Palucci, I., & Delogu, G. (2018) · Chemotherapy · doi:10.1159/000490478 · Cited by 101
Adjunctive Host-Directed Therapy With Statins Improves Tuberculosis-Related Outcomes in Mice
Dutta, N. K., Bruiners, N., Zimmerman, M. D., Tan, S., Dartois, V. A., Gennaro, M. L., & Karakousis, P. C. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz517 · Cited by 90
Randomized Trial of Metformin With Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults With Pulmonary Tuberculosis
Padmapriydarsini, C., Mamulwar, M., Mohan, A., Shanmugam, P., Gomathy, N. S., Mane, A., Singh, U. B., Pavankumar, N., Kadam, A., Kumar, H., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab964 · Cited by 90
Host stress drives tolerance and persistence: The bane of anti-microbial therapeutics
Hélaine, S., Conlon, B. P., Davis, K. M., & Russell, D. G. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.04.019 · Cited by 90
Addressing diabetes mellitus as part of the strategy for ending TB
Harries, A. D., Kumar, A. M. V., Satyanarayana, S., Lin, Y., Zachariah, R., Lönnroth, K., & Kapur, A. (2016) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trv111 · Cited by 91
Is metformin poised for a second career as an antimicrobial?
Malik, F. R., Mehdi, S. F., Ali, H., Patel, P., Basharat, A., Kumar, A., Ashok, F., Stein, J., Brima, W., Malhotra, P., et al. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2975 · Cited by 89
Inhibition of Fatty Acid Oxidation Promotes Macrophage Control of Mycobacterium tuberculosis
Chandra, P., He, L., Zimmerman, M. D., Yang, G., Köster, S., Ouimet, M. I., Wang, H., Moore, K. J., Dartois, V. A., Schilling, J. D., et al. (2020) · mBio · doi:10.1128/mbio.01139-20 · Cited by 88
The Interaction of Diabetes and Tuberculosis: Translating Research to Policy and Practice
van Crevel, R., & Critchley, J. (2021) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed6010008 · Cited by 91
AMP-Activated Protein Kinase and Host Defense against Infection
Silwal, P., Kim, J. K., Yuk, J., & Jo, E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113495 · Cited by 82
Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis
Krug, S., Parveen, S., & Bishai, W. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660916 · Cited by 85
Mycobacterium tuberculosis : Pathogenesis and therapeutic targets
Yang, J., Zhang, L., Qiao, W., & Luo, Y. (2023) · MedComm · doi:10.1002/mco2.353 · Cited by 91
Metformin Mediates Protection against Legionella Pneumonia through Activation of AMPK and Mitochondrial Reactive Oxygen Species
Kajiwara, C., Kusaka, Y., Kimura, S., Yamaguchi, T., Nanjo, Y., Ishii, Y., Udono, H., Standiford, T. J., & Tateda, K. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700474 · Cited by 83
AMPK directly phosphorylates TBK1 to integrate glucose sensing into innate immunity
Zhang, Q., Liu, S., Zhang, C., Wu, Q., Yu, X., Zhou, R., Meng, F., Wang, A., Zhang, F., Chen, S., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.10.026 · Cited by 85
How macrophage heterogeneity affects tuberculosis disease and therapy
Russell, D. G., Simwela, N. V., Mattila, J. T., Flynn, J. L., Mwandumba, H. C., & Pisu, D. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-024-01124-3 · Cited by 90
Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuits
Böhme, J., Martínez, N., Li, S., Lee, A., Marzuki, M., Tizazu, A. M., Ackart, D. F., Haugen, J. D., Todd, A., Lachmandas, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19095-z · Cited by 84
Self-citation
The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus
Lee, Y. J., Han, S. K., Park, J. H., Lee, J., Kim, D. K., Chung, H. S., & Heo, E. Y. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.249 · Cited by 79
Metabolic reprogramming & inflammation: Fuelling the host response to pathogens
Gleeson, L. E., & Sheedy, F. J. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.10.007 · Cited by 78
A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug?
Maniar, K., Moideen, A., Mittal, A., Patil, A., Chakrabarti, A., & Banerjee, D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.003 · Cited by 75
Metformin promotes innate immunity through a conserved PMK-1/p38 MAPK pathway
Xiao, Y., Liu, F., Li, S., Jiang, N., Yu, C., Zhu, X., Qin, Y., Hui, J., Meng, L., Song, C., et al. (2019) · Virulence · doi:10.1080/21505594.2019.1706305 · Cited by 74
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis
Zumla, A. I., Rao, M., Dodoo, E., & Maeurer, M. J. (2016) · BMC Medicine · doi:10.1186/s12916-016-0635-1 · Cited by 73
Tuberculosis and diabetes: current state and future perspectives
Pizzol, D., Gennaro, F. D., Chhaganlal, K. D., Fabrizio, C., Monno, L., Putoto, G., & Saracino, A. (2016) · Tropical Medicine & International Health · doi:10.1111/tmi.12704 · Cited by 72
Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response
Pereira, F. V., de Melo, A. C. L., Low, J. S., de Castro, Í. A., Braga, T. T., de Almeida, D. C., de Lima, A. G. U. B., Hiyane, M. I., Corrêa-Costa, M., Andrade‐Oliveira, V., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25380 · Cited by 75
Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells
Mishra, A. K., & Dingli, D. (2019) · Leukemia · doi:10.1038/s41375-019-0470-4 · Cited by 72
Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes
Ronacher, K., van Crevel, R., Critchley, J., Bremer, A. A., Schlesinger, L. S., Kapur, A., Basaraba, R. J., Kornfeld, H., & Restrepo, B. I. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.02.032 · Cited by 72
Host-Directed Therapies for Tuberculosis
Jeong, E.-K., Lee, H.-J., & Jung, Y. (2022) · Pathogens · doi:10.3390/pathogens11111291 · Cited by 74
Autophagy-activating strategies to promote innate defense against mycobacteria
Kim, Y. S., Silwal, P., Kim, S. Y., Yoshimori, T., & Jo, E. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0290-7 · Cited by 69
Host Cell Death and Modulation of Immune Response against Mycobacterium tuberculosis Infection
Vu, A., Glassman, I., Campbell, G., Yeganyan, S., Nguyen, J., Shin, A., & Venketaraman, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116255 · Cited by 73
Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review
Yu, X., Li, L., Xia, L., Feng, X., Chen, F., Cao, S., & Wei, X. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4548-4 · Cited by 66
Host-Directed Therapy as a Novel Treatment Strategy to Overcome Tuberculosis: Targeting Immune Modulation
Ahmed, S., Raqib, R., Gudmundsson, G. H., Bergman, P., Agerberth, B., & Rekha, R. S. (2020) · Antibiotics · doi:10.3390/antibiotics9010021 · Cited by 69
Chemical modulation of SQSTM1/p62-mediated xenophagy that targets a broad range of pathogenic bacteria
Lee, Y. J., Kim, J. K., Jung, C. H., Kim, Y. J., Jung, E. J., Lee, S. H., Choi, H. R., Son, Y. S., Shim, S. M., Jeon, S. M., et al. (2022) · Autophagy · doi:10.1080/15548627.2022.2054240 · Cited by 67
Persistent inflammation during anti-tuberculosis treatment with diabetes comorbidity
Kumar, N. P., Fukutani, K. F., Shruthi, B. S., Alves, T., Silveira-Mattos, P. S., Rocha, M. S., West, K., Natarajan, M., Viswanathan, V., Babu, S., et al. (2019) · eLife · doi:10.7554/elife.46477 · Cited by 66
Metformin: Candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients
Restrepo, B. I. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.09.008 · Cited by 63
Peptidyl-prolyl isomerase-B is involved in Mycobacterium tuberculosis biofilm formation and a generic target for drug repurposing-based intervention
Kumar, A., Alam, A., Grover, S., Pandey, S., Tripathi, D., Kumari, M., Rani, M., Singh, A., Akhter, Y., Ehtesham, N., et al. (2019) · npj Biofilms and Microbiomes · doi:10.1038/s41522-018-0075-0 · Cited by 53
Metformin Induces Cell Cycle Arrest, Reduced Proliferation, Wound Healing Impairment In Vivo and Is Associated to Clinical Outcomes in Diabetic Foot Ulcer Patients
Ochoa-González, F. D. L., Cervantes-Villagrana, A. R., Fernández-Ruiz, J. C., Nava-Ramirez, H. S., Hernandez-Correa, A. C., Enciso‐Moreno, J. A., & Castañeda‐Delgado, J. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150900 · Cited by 64
Metformin Decreases Risk of Tuberculosis Infection in Type 2 Diabetes Patients
Tseng, C. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7090264 · Cited by 64
Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection
O’Connor, G., Krishnan, N., Fagan-Murphy, A., Cassidy, J. P., O’Leary, S. M., Robertson, B. D., Keane, J., O’Sullivan, M. P., & Cryan, S. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.10.020 · Cited by 63
Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs
Rodrigues, L., Cravo, P., & Viveiros, M. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1760845 · Cited by 65
The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications
Girardi, E., Schepisi, M. S., Goletti, D., Bates, M., Mwaba, P., Yeboah‐Manu, D., Ntoumi, F., Palmieri, F., Maeurer, M. J., Zumla, A. I., et al. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.01.018 · Cited by 66
Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs
Chauhan, A., Kumar, M., Kumar, A., & Kanchan, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119301 · Cited by 66
Metformin as a potential combination therapy with existing front-line antibiotics for Tuberculosis
Vashisht, R., & Brahmachari, S. K. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0443-y · Cited by 62
Tuberculosis and comorbidities: treatment challenges in patients with comorbid diabetes mellitus and depression
Caceres-Cardenas, G., Calderón, R., & Ugarte‐Gil, C. (2022) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361221095831 · Cited by 80
The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment
Pan, S., Yen, Y., Kou, Y. R., Chuang, P., Su, V. Y., Feng, J., Chan, Y., & Su, W. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.11.040 · Cited by 60
Targeting immunometabolism in host defence against Mycobacterium tuberculosis
Sheedy, F. J., & Divangahi, M. (2020) · Immunology · doi:10.1111/imm.13276 · Cited by 62
Repurposing Immunomodulatory Drugs to Combat Tuberculosis
Fatima, S., Bhaskar, A., & Dwivedi, V. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645485 · Cited by 58
Metformin as Host-Directed Therapy for TB Treatment: Scoping Review
Naicker, N., Sigal, A., & Naidoo, K. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00435 · Cited by 55
Understanding Metabolic Regulation Between Host and Pathogens: New Opportunities for the Development of Improved Therapeutic Strategies Against Mycobacterium tuberculosis Infection
Park, J.-H., Shim, D., Kim, K. E. S., Lee, W., & Shin, S. J. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.635335 · Cited by 57
Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance
Lohrasbi, V., Talebi, M., Bialvaei, A. Z., Fattorini, L., Drancourt, M., Heidary, M., & Darban‐Sarokhalil, D. (2017) · Tuberculosis · doi:10.1016/j.tube.2017.12.002 · Cited by 57
Metformin as a Potential Adjuvant Antimicrobial Agent Against Multidrug Resistant Bacteria
Masadeh, M. M., Alzoubi, K. H., Masadeh, M. M., & Aburashed, Z. O. (2021) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s297903 · Cited by 55
Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment
Omoteso, O. A., Fadaka, A. O., Walker, R. B., & Khamanga, S. M. (2025) · Microorganisms · doi:10.3390/microorganisms13040722 · Cited by 65

Authors: Singhal, A., Jie, L., Kumar, P., Hong, G. S., Leow, M. K.-S., Paleja, B., Tsenova, L., Kurepina, N., Chen, J., Zolezzi, F., Kreiswirth, B., Poidinger, M., Chee, C., Kaplan, G., Wang, Y. T., & De Libero, G.
Affiliations: Agency for Science, Technology and Research (SG)
Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore 138648, Singapore.
Tan Tock Seng Hospital (SG)
Rutgers, The State University of New Jersey (US)
Corresponding author: Singhal, Amit
Kumar, Pavanish
ORCID: Singhal, Amit
Kumar, Pavanish
Leow, Melvin Khee-Shing
Paleja, Bhairav
Chen, Jinmiao
Zolezzi, Francesca
Kreiswirth, Barry
Poidinger, Michael
Chee, Cynthia
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2014-11-19
Volume: 6
Issue: 263
Pages: 263ra159-263ra159
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.3009885
OpenAlex: W2105296171
Cited by: 547
References: 49
Citations by year: 2026: 39 · 2025: 44 · 2024: 44 · 2023: 35 · 2022: 51 · 2021: 64 · 2020: 71 · 2019: 53 · 2018: 51 · 2017: 33 · 2016: 35 · 2015: 24 · 2014: 2
FWCI: 22.03
Type: journal article
Language: en
Open access: closed
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
National University of Singapore (submittedVersion)
edoc (University of Basel) (submittedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
Keywords: metformin, tuberculosis, Mycobacterium tuberculosis, AMPK, host-directed therapy, drug-resistant tuberculosis, reactive oxygen species, phagosome-lysosome fusion, host immune response, chronic inflammation
MeSH terms: Humans, Metformin, Microbial Sensitivity Tests, Mycobacterium tuberculosis, Tuberculosis, Reactive Oxygen Species

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metformin as adjunct antituberculosis therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks